title: Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP).
abstract: BACKGROUND
  The Systolic Hypertension in the Elderly Program (SHEP) demonstrated that treating isolated systolic hypertension in older patients decreased incidence of total stroke, but whether all types of stroke were reduced was not evaluated.
  
  
  OBJECTIVE
  To investigate antihypertensive drug treatment effects on incidence of stroke by type and subtype, timing of strokes, case-fatality rates, stroke residual effects, and relationship of attained systolic blood pressure to stroke incidence.
  
  
  METHODS
  The SHEP study, a randomized, double-blind, placebo-controlled trial began March 1, 1985, and had an average follow-up of 4.5 years.
  
  
  METHODS
  A total of 4736 men and women aged 60 years or older with isolated systolic hypertension at 16 clinical centers in the United States.
  
  
  METHODS
  Patients were randomly assigned to receive treatment with 12.5 mg/d of chlorthalidone (step 1); either 25 mg/d of atenolol or 0.05 mg/d of reserpine (step 2) could be added (n = 2365); or placebo (n = 2371).
  
  
  METHODS
  Occurrence, type and subtype, and timing of first strokes and stroke fatalities; and change in stroke incidence for participants (whether in active treatment or placebo groups) reaching study-specific systolic blood pressure goal (decrease of at least 20 mm Hg from baseline to below 160 mm Hg) compared with participants not reaching goal.
  
  
  RESULTS
  A total of 85 and 132 participants in the active treatment and placebo groups, respectively, had ischemic strokes (adjusted relative risk [RR], 0.63; 95% confidence interval [CI], 0.48-0.82); 9 and 19 had hemorrhagic strokes (adjusted RR, 0.46; 95% CI, 0.21-1.02); and 9 and 8 had strokes of unknown type (adjusted RR, 1.05; 95% CI, 0.40-2. 73), respectively. Four subtypes of ischemic stroke were observed in active treatment and placebo group participants, respectively, as follows: for lacunar, n = 23 and n = 43 (adjusted RR, 0.53; 95% CI, 0.32-0.88); for embolic, n = 9 and n = 16 (adjusted RR, 0.56; 95% CI, 0.25-1.27); for atherosclerotic, n = 13 and n = 13 (adjusted RR, 0. 99; 95% CI, 0.46-2.15); and for unknown subtype, n = 40 and n = 60 (adjusted RR, 0.64; 95% CI, 0.43-0.96). Treatment effect was observed within 1 year for hemorrhagic strokes but was not seen until the second year for ischemic strokes. Stroke incidence significantly decreased in participants attaining study-specific systolic blood pressure goals.
  
  
  CONCLUSIONS
  In this study, antihypertensive drug treatment reduced the incidence of both hemorrhagic and ischemic (including lacunar) strokes. Reduction in stroke incidence occurred when specific systolic blood pressure goals were attained. JAMA. 2000;284:465-471
authors.affiliation: Washington University, Box 8048, 660 S Euclid Ave, St Louis, MO 63110, USA. mperry@imgate.wustl.edu
authors.forename: H M
authors.initials: HM
authors.lastname: Perry
authors.forename: B R
authors.initials: BR
authors.lastname: Davis
authors.forename: T R
authors.initials: TR
authors.lastname: Price
authors.forename: W B
authors.initials: WB
authors.lastname: Applegate
authors.forename: W S
authors.initials: WS
authors.lastname: Fields
authors.forename: J M
authors.initials: JM
authors.lastname: Guralnik
authors.forename: L
authors.initials: L
authors.lastname: Kuller
authors.forename: S
authors.initials: S
authors.lastname: Pressel
authors.forename: J
authors.initials: J
authors.lastname: Stamler
authors.forename: J L
authors.initials: JL
authors.lastname: Probstfield
mesh_terms: D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001262:Atenolol / Q000627:therapeutic use; D002545:Brain Ischemia / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D002543:Cerebral Hemorrhage / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D002752:Chlorthalidone / Q000627:therapeutic use; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D015994:Incidence; D008297:Male; D008875:Middle Aged; D012110:Reserpine / Q000627:therapeutic use; D020521:Stroke / Q000145:classification / Q000453:epidemiology / Q000401:mortality / Q000517:prevention & control*; D013599:Systole
chemical_list: D000959:Antihypertensive Agents; D001262:Atenolol; D012110:Reserpine; D002752:Chlorthalidone